New hope for thyroid eye disease: antibody therapy after steroids shows promise

NCT ID NCT07152366

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 26 times

Summary

This study tests a drug called tetuzumab (IBI311) in people with moderate to severe thyroid eye disease (TAO) who did not get enough help from steroids. The drug blocks a protein that fuels inflammation and tissue swelling behind the eyes. About 96 adults will receive the treatment to see if it reduces eye bulging and redness. The goal is to control the disease and improve symptoms, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Changzheng Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200003, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.